21 documents

Read All
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Aprea reports Phase Ib/II response data for APR-246 in MDS

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome...
Read More
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
Read More
19:51 , May 25, 2017 |  BC Week In Review  |  Clinical News

Aprea starts Phase Ib/II of APR-246 for MDS

Aprea Therapeutics AB (Solna, Sweden) began an open-label, U.S. Phase Ib/II trial to evaluate APR-246 in about 60 patients with tumor protein p53 (TP53; p53) mutant myelodysplastic syndrome (MDS). The dose-escalation Phase I part will...
Read More
17:15 , Apr 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53-mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines, high levels...
Read More
19:12 , Dec 15, 2016 |  BC Innovations  |  Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...
Read More
17:34 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

APR-246: Additional Ph Ib data

Additional data from 22 evaluable patients with platinum-sensitive, high-grade serous ovarian cancer in the Phase Ib portion of the international Phase Ib/II PiSARRO trial showed that second-line treatment with IV APR-246 plus carboplatin and pegylated...
Read More
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
Read More
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

APR-246: Additional Phase Ib data

Data from 24 evaluable patients with platinum-sensitive, high-grade serous ovarian cancer in the Phase Ib portion of the European Phase Ib/II PiSARRO trial showed that second-line treatment with IV APR-246 plus carboplatin and pegylated liposomal...
Read More
07:00 , May 16, 2016 |  BioCentury  |  Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
Read More
07:00 , Apr 11, 2016 |  BioCentury  |  Emerging Company Profile

Restoring p53

PMV Pharmaceuticals Inc. is developing allele-specific small molecules for cancer that bind mutant p53 and restore the protein's wild-type conformation and tumor-suppressing function. PMV's compounds could be more selective for cancer cells than a more...
Read More